# reload+after+2024-01-20 07:47:03.630914
address1§1222 Demonbreun Street
address2§Suite 2000
city§Nashville
state§TN
zip§37203
country§United States
phone§615 724 7755
fax§510 742 3401
website§https://www.revance.com
industry§Biotechnology
sector§Healthcare
longBusinessSummary§Revance Therapeutics, Inc., a biotechnology company, engages in the development, manufacture, and commercialization of neuromodulators for various aesthetic and therapeutic indications in the United States and internationally. The company's lead drug candidate is DaxibotulinumtoxinA for injection, which has completed phase III clinical trials for the treatment of glabellar (frown) lines and cervical dystonia; is in phase II clinical trials to treat upper facial lines, moderate or severe dynamic forehead lines, and moderate or severe lateral canthal lines; and has completed Phase II clinical trials for the treatment of adult upper limb spasticity and plantar fasciitis. It is also developing OnabotulinumtoxinA, a biosimilar to BOTOX. The company also offers Resilient Hyaluronic Acid (RHA) dermal filler for the correction of moderate to severe dynamic facial wrinkles; RHA Redensity, a dermal filler for the treatment of moderate to severe dynamic perioral rhytids; and OPUL Relational Commerce Platform, a financial technology platform. It has a collaboration and license agreement with Viatris Inc. to develop, manufacture, and commercialize onabotulinumtoxinA. The company was formerly known as Essentia Biosystems, Inc. and changed its name to Revance Therapeutics, Inc. in April 2005. Revance Therapeutics, Inc. was incorporated in 1999 and is headquartered in Nashville, Tennessee.
fullTimeEmployees§534
companyOfficers§[{'maxAge': 1, 'name': 'Mr. Mark J. Foley', 'age': 58, 'title': 'CEO & Director', 'yearBorn': 1965, 'fiscalYear': 2022, 'totalPay': 1328701, 'exercisedValue': 0, 'unexercisedValue': 3890465}, {'maxAge': 1, 'name': 'Mr. Dustin S. Sjuts', 'age': 43, 'title': 'President', 'yearBorn': 1980, 'fiscalYear': 2022, 'totalPay': 911668, 'exercisedValue': 0, 'unexercisedValue': 75947}, {'maxAge': 1, 'name': 'Mr. Tobin C. Schilke', 'age': 48, 'title': 'CFO & Principal Accounting Officer', 'yearBorn': 1975, 'fiscalYear': 2022, 'totalPay': 753684, 'exercisedValue': 0, 'unexercisedValue': 112452}, {'maxAge': 1, 'name': 'Mr. Dwight  Moxie', 'age': 47, 'title': 'Senior VP, General Counsel & Corporate Secretary', 'yearBorn': 1976, 'fiscalYear': 2022, 'totalPay': 743774, 'exercisedValue': 0, 'unexercisedValue': 76321}, {'maxAge': 1, 'name': 'Jessica  Serra', 'title': 'Head of Investor Relations & ESG', 'fiscalYear': 2022, 'exercisedValue': 0, 'unexercisedValue': 0}, {'maxAge': 1, 'name': 'Ms. Jeanie D. Herbert', 'title': 'Senior Director of Investor Relations & Corporate Communications', 'fiscalYear': 2022, 'exercisedValue': 0, 'unexercisedValue': 0}, {'maxAge': 1, 'name': 'Ms. Taryn  Conway', 'title': 'Vice President of Marketing', 'fiscalYear': 2022, 'exercisedValue': 0, 'unexercisedValue': 0}, {'maxAge': 1, 'name': 'Ms. Amie  Krause', 'title': 'Chief People Officer', 'fiscalYear': 2022, 'exercisedValue': 0, 'unexercisedValue': 0}, {'maxAge': 1, 'name': 'Dr. Conor  Gallagher', 'title': 'Head of Medical Affairs & Aesthetics', 'fiscalYear': 2022, 'exercisedValue': 0, 'unexercisedValue': 0}, {'maxAge': 1, 'name': 'Dr. David A. Hollander M.B.A., M.D.', 'age': 49, 'title': 'Chief Medical Officer', 'yearBorn': 1974, 'fiscalYear': 2022, 'exercisedValue': 0, 'unexercisedValue': 0}]
auditRisk§6
boardRisk§5
compensationRisk§7
shareHolderRightsRisk§7
overallRisk§6
governanceEpochDate§1704067200
compensationAsOfEpochDate§1672444800
maxAge§86400
priceHint§2
payoutRatio§0.0
beta§0.92
priceToSalesTrailing12Months§3.4237764
currency§USD
dateShortInterest§1702598400
forwardEps§-1.93
pegRatio§-0.21
exchange§NGM
quoteType§EQUITY
shortName§Revance Therapeutics, Inc.
longName§Revance Therapeutics, Inc.
firstTradeDateEpochUtc§1391697000
timeZoneFullName§America/New_York
timeZoneShortName§EST
uuid§314464b1-77ff-3813-807b-b0498e551d76
gmtOffSetMilliseconds§-18000000
targetHighPrice§42.0
targetLowPrice§9.0
targetMeanPrice§25.18
targetMedianPrice§25.0
recommendationMean§1.9
recommendationKey§buy
numberOfAnalystOpinions§11
quickRatio§3.964
grossMargins§0.17846
ebitdaMargins§-0.99742997
trailingPegRatio§None
